Inclusion Criteria:  Age 18-65 years old; HIV serology is positive; Volunteer to participate; CD4+T cell count >100 and <350 cells/mm3; People who have received HAART treatment and the viral load is undetected for at least 2 years, but have immune reconstitution disorder; Without active opportunistic infection;  Exclusion Criteria:  History of allergy or contraindications to Zadaxin; Skin basal cell carcinoma, cervical carcinoma in situ or other concurrent tumors other than Kaposi's sarcoma; The expected survival time is less than 1 year; Women of childbearing age have a positive pregnancy test; Major heart disease or central nervous system disease or other nervous system abnormalities; ACTG-AIDS dementia syndrome staging score> 0.5; Organ transplantation; Received chemotherapy and radiotherapy for malignant tumors within 6 months; Known immunomodulators (such as systemic steroids, interferons, interleukins) or other immunotherapy within 30 days before the start of the study; Blood transfusion within 30 days before the start of the study; Have a history of iritis, endophthalmitis, scleritis or retinitis; Within 30 days before the screening assessment, accept any experimental treatment for HIV-positive patients with or without symptoms of infection; Drug abuse; The doctor's decision is that participation in the trial is not in the patient's best interests, or any situation that does not allow safe compliance with the protocol.